On the heels of COVID-19 pacts with Bayer and GlaxoSmithKline, CureVac is joining forces with the UK government to tackle the next challenge—new variants of the SARS-CoV-2 virus. Under the agreement, CureVac and the UK Vaccines Taskforce will study multiple variants of the virus and develop vaccine candidates against selected variants. The government will expedite clinical trials in the UK to get vaccines through emergency or conditional authorizations as quickly as possible. Source: Fierce Biotech 5/2/21